GOSS vs MNKD vs KO vs UTHR vs NKTR

For growth investors, MannKind Corporation (MNKD) is the stronger pick with 22.

2% revenue growth year-over-year, versus -57. 7% for Gossamer Bio, Inc. (GOSS). United Therapeutics Corporation (UTHR) offers the better valuation at 19. 6x trailing P/E (19. 2x forward), making it the more compelling value choice. Analysts rate Gossamer Bio, Inc. (GOSS) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, United Therapeutics Corporation (UTHR) is the cheapest at 19.

6x versus MannKind Corporation at 183. 0x. On forward P/E, United Therapeutics Corporation is actually cheaper at 19. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: United Therapeutics Corporation wins at 1. 00x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, United Therapeutics Corporation (UTHR) delivered a total return of +203.

9%, compared to -98. 2% for Gossamer Bio, Inc. (GOSS). Over 10 years, the gap is even starker: UTHR returned +396. 1% versus GOSS's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Gossamer Bio, Inc. 's 2. 45β — meaning GOSS is approximately -1322% more volatile than KO relative to the S&P 500. On balance sheet safety, The Coca-Cola Company (KO) carries a lower debt/equity ratio of 133% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), MannKind Corporation (MNKD) is pulling ahead at 22.

2% versus -57. 7% for Gossamer Bio, Inc. (GOSS). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -200. 0% for Gossamer Bio, Inc.. Over a 3-year CAGR, MNKD leads at 51. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

United Therapeutics Corporation (UTHR) is the more profitable company, earning 41.

9% net margin versus -351. 5% for Gossamer Bio, Inc. — meaning it keeps 41. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTHR leads at 47. 7% versus -336. 8% for GOSS. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, United Therapeutics Corporation (UTHR) is the more undervalued stock at a PEG of 1. 00x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, United Therapeutics Corporation (UTHR) trades at 19. 2x forward P/E versus 25. 3x for The Coca-Cola Company — 6. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GOSS: 373. 6% to $0. 77.

In this comparison, KO (2.

5% yield) pays a dividend. GOSS, MNKD, UTHR, NKTR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Gossamer Bio, Inc. (GOSS) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, GOSS: -99. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (GOSS (Healthcare) and MNKD (Healthcare) and KO (Consumer Defensive) and UTHR (Healthcare) and NKTR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GOSS is a small-cap quality compounder stock; MNKD is a small-cap high-growth stock; KO is a large-cap quality compounder stock; UTHR is a mid-cap quality compounder stock; NKTR is a small-cap quality compounder stock. KO pays a dividend while GOSS, MNKD, UTHR, NKTR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.